Logo image of SGRY

SURGERY PARTNERS INC (SGRY) Stock Fundamental Analysis

NASDAQ:SGRY - Nasdaq - US86881A1007 - Common Stock - Currency: USD

22.15  +0.13 (+0.59%)

After market: 22.15 0 (0%)

Fundamental Rating

3

Overall SGRY gets a fundamental rating of 3 out of 10. We evaluated SGRY against 103 industry peers in the Health Care Providers & Services industry. SGRY has a medium profitability rating, but doesn't score so well on its financial health evaluation. SGRY has a correct valuation and a medium growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

In the past year SGRY was profitable.
SGRY had a positive operating cash flow in the past year.
SGRY had negative earnings in each of the past 5 years.
In the past 5 years SGRY always reported a positive cash flow from operatings.
SGRY Yearly Net Income VS EBIT VS OCF VS FCFSGRY Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

1.2 Ratios

The Return On Assets of SGRY (-2.43%) is comparable to the rest of the industry.
SGRY's Return On Equity of -11.11% is on the low side compared to the rest of the industry. SGRY is outperformed by 62.14% of its industry peers.
SGRY has a Return On Invested Capital (5.07%) which is comparable to the rest of the industry.
Measured over the past 3 years, the Average Return On Invested Capital for SGRY is below the industry average of 9.71%.
The 3 year average ROIC (5.03%) for SGRY is below the current ROIC(5.07%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA -2.43%
ROE -11.11%
ROIC 5.07%
ROA(3y)-1.04%
ROA(5y)-1.46%
ROE(3y)-4.24%
ROE(5y)-9.69%
ROIC(3y)5.03%
ROIC(5y)4.49%
SGRY Yearly ROA, ROE, ROICSGRY Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 60 80

1.3 Margins

With an excellent Operating Margin value of 14.92%, SGRY belongs to the best of the industry, outperforming 86.41% of the companies in the same industry.
In the last couple of years the Operating Margin of SGRY has remained more or less at the same level.
SGRY's Gross Margin of 26.51% is in line compared to the rest of the industry. SGRY outperforms 51.46% of its industry peers.
SGRY's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 14.92%
PM (TTM) N/A
GM 26.51%
OM growth 3Y3.68%
OM growth 5Y1.41%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.83%
GM growth 5Y-0.73%
SGRY Yearly Profit, Operating, Gross MarginsSGRY Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 20 30

More info and screens

2

2. Health

2.1 Basic Checks

SGRY has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
The number of shares outstanding for SGRY has been increased compared to 1 year ago.
Compared to 5 years ago, SGRY has more shares outstanding
Compared to 1 year ago, SGRY has a worse debt to assets ratio.
SGRY Yearly Shares OutstandingSGRY Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
SGRY Yearly Total Debt VS Total AssetsSGRY Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

2.2 Solvency

SGRY has an Altman-Z score of 0.81. This is a bad value and indicates that SGRY is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 0.81, SGRY is doing worse than 71.84% of the companies in the same industry.
The Debt to FCF ratio of SGRY is 20.49, which is on the high side as it means it would take SGRY, 20.49 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of SGRY (20.49) is worse than 60.19% of its industry peers.
A Debt/Equity ratio of 1.98 is on the high side and indicates that SGRY has dependencies on debt financing.
Looking at the Debt to Equity ratio, with a value of 1.98, SGRY is doing worse than 74.76% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 1.98
Debt/FCF 20.49
Altman-Z 0.81
ROIC/WACC0.61
WACC8.37%
SGRY Yearly LT Debt VS Equity VS FCFSGRY Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1B 2B 3B

2.3 Liquidity

A Current Ratio of 1.89 indicates that SGRY should not have too much problems paying its short term obligations.
The Current ratio of SGRY (1.89) is better than 70.87% of its industry peers.
A Quick Ratio of 1.73 indicates that SGRY should not have too much problems paying its short term obligations.
The Quick ratio of SGRY (1.73) is better than 66.02% of its industry peers.
Industry RankSector Rank
Current Ratio 1.89
Quick Ratio 1.73
SGRY Yearly Current Assets VS Current LiabilitesSGRY Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

5

3. Growth

3.1 Past

The earnings per share for SGRY have decreased strongly by -12.87% in the last year.
The Revenue has grown by 13.54% in the past year. This is quite good.
SGRY shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 11.20% yearly.
EPS 1Y (TTM)-12.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-60%
Revenue 1Y (TTM)13.54%
Revenue growth 3Y11.86%
Revenue growth 5Y11.2%
Sales Q2Q%8.17%

3.2 Future

Based on estimates for the next years, SGRY will show a very strong growth in Earnings Per Share. The EPS will grow by 23.05% on average per year.
Based on estimates for the next years, SGRY will show a quite strong growth in Revenue. The Revenue will grow by 10.13% on average per year.
EPS Next Y-4.47%
EPS Next 2Y9.79%
EPS Next 3Y15.26%
EPS Next 5Y23.05%
Revenue Next Year9.65%
Revenue Next 2Y9.49%
Revenue Next 3Y9.68%
Revenue Next 5Y10.13%

3.3 Evolution

The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
SGRY Yearly Revenue VS EstimatesSGRY Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 1B 2B 3B 4B 5B
SGRY Yearly EPS VS EstimatesSGRY Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 0 1 -1 2 -2

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 25.17, the valuation of SGRY can be described as expensive.
61.16% of the companies in the same industry are more expensive than SGRY, based on the Price/Earnings ratio.
When comparing the Price/Earnings ratio of SGRY to the average of the S&P500 Index (27.45), we can say SGRY is valued inline with the index average.
Based on the Price/Forward Earnings ratio of 19.55, the valuation of SGRY can be described as rather expensive.
61.16% of the companies in the same industry are more expensive than SGRY, based on the Price/Forward Earnings ratio.
The average S&P500 Price/Forward Earnings ratio is at 21.90. SGRY is around the same levels.
Industry RankSector Rank
PE 25.17
Fwd PE 19.55
SGRY Price Earnings VS Forward Price EarningsSGRY Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

68.93% of the companies in the same industry are more expensive than SGRY, based on the Enterprise Value to EBITDA ratio.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of SGRY indicates a somewhat cheap valuation: SGRY is cheaper than 70.87% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 16.38
EV/EBITDA 9.8
SGRY Per share dataSGRY EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 -10 20 -20

4.3 Compensation for Growth

SGRY's earnings are expected to grow with 15.26% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y9.79%
EPS Next 3Y15.26%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SGRY!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SURGERY PARTNERS INC

NASDAQ:SGRY (7/3/2025, 8:08:57 PM)

After market: 22.15 0 (0%)

22.15

+0.13 (+0.59%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)05-12 2025-05-12/bmo
Earnings (Next)08-04 2025-08-04/bmo
Inst Owners71.88%
Inst Owner Change0.04%
Ins Owners1.32%
Ins Owner Change0.88%
Market Cap2.84B
Analysts80
Price Target32.49 (46.68%)
Short Float %12.34%
Short Ratio6.55
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-4.69%
Min EPS beat(2)-24.34%
Max EPS beat(2)14.96%
EPS beat(4)2
Avg EPS beat(4)-8.11%
Min EPS beat(4)-26.04%
Max EPS beat(4)14.96%
EPS beat(8)6
Avg EPS beat(8)33.9%
EPS beat(12)8
Avg EPS beat(12)145.55%
EPS beat(16)11
Avg EPS beat(16)116.96%
Revenue beat(2)1
Avg Revenue beat(2)0.12%
Min Revenue beat(2)-2.1%
Max Revenue beat(2)2.34%
Revenue beat(4)2
Avg Revenue beat(4)-0.02%
Min Revenue beat(4)-2.1%
Max Revenue beat(4)2.34%
Revenue beat(8)3
Avg Revenue beat(8)-0.73%
Revenue beat(12)4
Avg Revenue beat(12)-1.04%
Revenue beat(16)6
Avg Revenue beat(16)-0.9%
PT rev (1m)0.21%
PT rev (3m)-1.23%
EPS NQ rev (1m)-10.26%
EPS NQ rev (3m)-31.73%
EPS NY rev (1m)-5.14%
EPS NY rev (3m)-16.79%
Revenue NQ rev (1m)-0.06%
Revenue NQ rev (3m)-0.44%
Revenue NY rev (1m)-0.15%
Revenue NY rev (3m)-0.06%
Valuation
Industry RankSector Rank
PE 25.17
Fwd PE 19.55
P/S 0.89
P/FCF 16.38
P/OCF 10.7
P/B 1.63
P/tB N/A
EV/EBITDA 9.8
EPS(TTM)0.88
EY3.97%
EPS(NY)1.13
Fwd EY5.11%
FCF(TTM)1.35
FCFY6.1%
OCF(TTM)2.07
OCFY9.35%
SpS24.76
BVpS13.58
TBVpS-26.77
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -2.43%
ROE -11.11%
ROCE 6.42%
ROIC 5.07%
ROICexc 5.23%
ROICexgc 18.9%
OM 14.92%
PM (TTM) N/A
GM 26.51%
FCFM 5.46%
ROA(3y)-1.04%
ROA(5y)-1.46%
ROE(3y)-4.24%
ROE(5y)-9.69%
ROIC(3y)5.03%
ROIC(5y)4.49%
ROICexc(3y)5.23%
ROICexc(5y)4.72%
ROICexgc(3y)18.5%
ROICexgc(5y)17.9%
ROCE(3y)6.37%
ROCE(5y)5.69%
ROICexcg growth 3Y0.78%
ROICexcg growth 5Y0.88%
ROICexc growth 3Y4.99%
ROICexc growth 5Y3.37%
OM growth 3Y3.68%
OM growth 5Y1.41%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.83%
GM growth 5Y-0.73%
F-Score3
Asset Turnover0.4
Health
Industry RankSector Rank
Debt/Equity 1.98
Debt/FCF 20.49
Debt/EBITDA 5.48
Cap/Depr 59.34%
Cap/Sales 2.9%
Interest Coverage 250
Cash Conversion 42.21%
Profit Quality N/A
Current Ratio 1.89
Quick Ratio 1.73
Altman-Z 0.81
F-Score3
WACC8.37%
ROIC/WACC0.61
Cap/Depr(3y)68.21%
Cap/Depr(5y)61.64%
Cap/Sales(3y)3.1%
Cap/Sales(5y)2.84%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-12.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-60%
EPS Next Y-4.47%
EPS Next 2Y9.79%
EPS Next 3Y15.26%
EPS Next 5Y23.05%
Revenue 1Y (TTM)13.54%
Revenue growth 3Y11.86%
Revenue growth 5Y11.2%
Sales Q2Q%8.17%
Revenue Next Year9.65%
Revenue Next 2Y9.49%
Revenue Next 3Y9.68%
Revenue Next 5Y10.13%
EBIT growth 1Y8.28%
EBIT growth 3Y15.97%
EBIT growth 5Y12.77%
EBIT Next Year47.27%
EBIT Next 3Y22.98%
EBIT Next 5YN/A
FCF growth 1Y159.43%
FCF growth 3Y92.28%
FCF growth 5Y30.27%
OCF growth 1Y72.9%
OCF growth 3Y51.04%
OCF growth 5Y18.3%